Belsomra (Suvorexant) Cost in Minnesota 2026: Pricing, Insurance & Savings

Belsomra is the brand name for suvorexant, an oral dual orexin receptor antagonist (DORA) approved by the FDA in 2014 for insomnia with difficulty initiating or maintaining sleep. This Schedule IV controlled substance comes in 10 mg, 15 mg, and 20 mg tablets, dosed once at bedtime. No FDA-approved generic formulation has been released to date.

The honest answer on cost is this: the stable facts about suvorexant are federal and clinical (its FDA approval, controlled-substance schedule, dosing range, and label warnings), while the dollar figures a Minnesota patient actually pays are not stable. Manufacturer list price, pharmacy cash price, insurer tier placement, and Medicaid prior-authorization criteria all change over time and by plan, and none of them were confirmed against a primary Minnesota-specific source for this draft. Any specific dollar amount below should be treated as a starting point for a phone call to a pharmacy or plan, not a number to budget around.

What is established versus what needs verification

Established (label-level, stable):

• Suvorexant received FDA approval in 2014 for insomnia.
• It is Schedule IV under the Controlled Substances Act.
• The FDA label lists somnolence, dizziness, and headache among common adverse effects, and warns against coadministration with strong CYP3A inhibitors.
• No FDA-approved generic suvorexant exists as of this draft's publication date.

Plausible but requiring current verification (volatile, plan- or pharmacy-specific):

• Any specific manufacturer list price or average Minnesota cash-pay price. These change with WAC updates, pharmacy contracts, and discount-card networks, and no state-specific pricing source was available to confirm a current figure for this article.
• Minnesota Medicaid (Medical Assistance) prior-authorization criteria and approval timelines. Medicaid preferred drug lists are typically reviewed on a recurring cycle, but the exact current criteria for suvorexant were not verified against a Minnesota Health Care Programs source for this draft.
• Individual commercial insurers' formulary tier, step-therapy rules, and copay ranges. These vary by specific plan and change at least annually; naming particular Minnesota insurers with specific tier numbers without a verified formulary document risks stating something that is already out of date or plan-specific.
• Manufacturer savings card terms (eligibility, maximum benefit, exclusions for government insurance). Manufacturer copay programs are a common industry practice for brand-name, non-generic drugs, but the exact current terms need to be confirmed on the manufacturer's own program page before quoting a dollar cap.

Minnesota Medicaid and suvorexant

Minnesota Medicaid programs commonly require prior authorization for brand-name, non-generic sleep medications, and it is reasonable to expect that a step-therapy requirement (trial of a lower-cost agent such as trazodone, doxepin, or a generic Z-drug) would be part of that process for suvorexant, consistent with how Medicaid programs generally handle non-preferred brand drugs. However, the specific current PA criteria, approval rate, and appeal window for Minnesota Medical Assistance were not confirmed against a Minnesota Health Care Programs (MHCP) document for this draft. A patient or clinician needing an authoritative answer should check the current MHCP formulary and PA criteria directly, or ask the prescribing clinic's prior-authorization staff, since these details can change between formulary review cycles and can differ across Minnesota Medicaid managed care organizations.

Commercial insurance coverage

Suvorexant, as a brand-name drug without a generic equivalent, is commonly placed on a non-preferred or preferred brand tier by commercial insurers, which typically means a higher copay than a generic sleep aid and sometimes a step-therapy requirement to try a generic first. That is a general pattern across commercial formularies for drugs in this position, not a Minnesota-specific finding. Exact tier placement, copay amount, and step-therapy rules differ by employer group and plan year, so a patient should confirm their own plan's current formulary listing rather than assume a figure from a general article applies to their coverage.

For patients on a high-deductible health plan, the full negotiated rate typically applies until the deductible is met, which is standard for any brand medication under an HDHP design, not something specific to suvorexant.

Manufacturer savings and patient assistance

The Belsomra manufacturer typically provides copay support for patients with commercial insurance and a separate assistance initiative for uninsured or lower-income individuals meeting specified financial requirements. Government insurance recipients, including those covered by Medicare or Medicaid, generally cannot access these programs due to federal regulations restricting copay subsidies. Patients should verify the current assistance terms, income limits, and application requirements directly through the official manufacturer program website prior to enrollment, as program details are subject to periodic revision.

Compounded suvorexant

Licensed 503A compounding pharmacies can legally prepare suvorexant from bulk drug substance pursuant to a valid, patient-specific prescription, under state board of pharmacy oversight and USP General Chapter 795 standards for non-sterile compounding. This is a general feature of pharmacy compounding law, applicable in most states including Minnesota, rather than something unique to this drug. One clinical scenario where compounding has genuine relevance: the FDA label describes a reduced 5 mg dose for patients taking a moderate CYP3A inhibitor, but no commercial 5 mg tablet is manufactured, so a 5 mg dose would need to come from a compounding pharmacy if a clinician determines it is appropriate.

A material limitation applies to any compounded product: compounded medications do not undergo FDA bioequivalence or batch-release testing the way an FDA-approved tablet does. The active ingredient may be pharmaceutically identical, but absorption can differ based on formulation and excipients. Patients considering a compounded alternative for cost reasons should discuss this tradeoff with their prescriber and confirm the pharmacy's current state licensure directly with the Minnesota Board of Pharmacy, rather than relying on a general claim that "compounded suvorexant is available in Minnesota."

Telehealth prescribing

Following the DEA's 2024 telemedicine framework for controlled substances, a synchronous audio-video evaluation can be sufficient to establish a prescriber-patient relationship for Schedule III-V medications, which includes suvorexant. State medical and pharmacy boards, including Minnesota's, generally align with this federal framework, but telehealth prescribing rules for controlled substances have been subject to repeated federal extensions and rule changes, so a patient or clinic relying on this pathway should confirm the current rule status rather than assume the 2024 framework is unchanged at the time of use.

How suvorexant compares to other insomnia medications

Unlike Z-drugs such as zolpidem and eszopiclone, which potentiate GABA-A signaling, suvorexant achieves its effect through antagonism of orexin receptors. A 2014 randomized controlled trial by Herring et al. in Lancet Neurology demonstrated that suvorexant enhanced subjective measures of sleep onset and sleep continuity relative to placebo across months of treatment; readers should reference the original publication to confirm specific effect magnitude values, as the database identifier used during manuscript preparation was not definitively validated. The American Academy of Sleep Medicine conditionally recommends suvorexant for chronic sleep maintenance insomnia in adults; for the guideline's precise recommendation language and evidentiary support, the published AASM guideline should be consulted directly.

Generic Z-drugs (zolpidem, generic trazodone, generic doxepin at low doses) are typically far cheaper at retail than any brand-name DORA, reflecting generic competition rather than a difference in FDA-approved indication. The clinical reason a prescriber might choose suvorexant over a cheaper generic is the orexin mechanism, which is associated with a different side-effect and dependence profile than GABA-A modulators in the class literature, but a lower price does not mean a Z-drug is interchangeable with suvorexant for every patient, and the choice depends on individual history (for example, prior complex sleep behaviors, substance use history, or contraindications) that should be discussed with the prescribing clinician rather than decided on cost alone.

Strategies that reduce out-of-pocket cost, without promising a number

• Ask the pharmacy for a cash-pay quote and compare it against your insurance copay before filling; for a non-preferred brand drug, the cash price with a discount card is sometimes lower than the insured copay.
• If commercially insured, ask whether a manufacturer savings card can be applied at the counter, and confirm current eligibility rules with the manufacturer program directly.
• If uninsured, ask the prescriber's office about manufacturer patient assistance programs, which generally require income documentation.
• If on Minnesota Medicaid, ask the prescribing clinic to submit prior authorization with documentation of a prior trial of a lower-cost agent, since that is the typical Medicaid pattern for non-preferred brand insomnia drugs.
• Mail-order or 90-day fills sometimes reduce per-unit cost for maintenance medications, but this depends on the specific plan's mail-order pricing, which should be checked before assuming a discount.

Do not split suvorexant tablets to save money. The tablets are film-coated, dose accuracy cannot be assured by splitting, and the manufacturer does not endorse this practice.

Safety and dosing background

The FDA label recommends starting at the lowest effective dose, taken within 30 minutes of bedtime with at least seven hours of intended sleep time remaining. Dose escalation from 10 mg to 20 mg is a decision for the prescribing clinician based on effectiveness and tolerability, not something a patient should adjust independently. Suvorexant should not be combined with strong CYP3A inhibitors such as ketoconazole or clarithromycin, because these increase drug exposure; the label describes a reduced dose consideration for moderate CYP3A inhibitor use. Anyone experiencing daytime impairment, sleep-related activity without full awareness (such as sleepwalking or sleep-driving), worsening mood, or suicidal thoughts while taking suvorexant should contact their prescriber promptly, and anyone with a mental health emergency should seek urgent or emergency care rather than waiting for a routine appointment.

This article does not provide individualized dosing advice. Dose selection, drug interaction screening, and treatment duration should be determined by the prescribing clinician based on the individual patient's health history.

Verification checklist: stable facts vs. facts that expire

Use this before quoting a price, coverage rule, or program benefit to a patient.

Stable facts (safe to state without a fresh date check):

• Suvorexant is FDA-approved for insomnia and classified as Schedule IV.
• No FDA-approved generic suvorexant tablet exists as of this draft.
• The FDA label describes a CYP3A drug interaction and recommends caution with strong inhibitors.
• Compounded suvorexant, where legally available, does not undergo FDA bioequivalence testing.

Facts that must be re-verified on the date of use, with a suggested source:

If a number in this checklist's second column cannot be confirmed on the date a patient needs it, tell the patient the figure is unverified rather than repeating an old number as current.

Frequently asked questions

Evidence boundary

Established: suvorexant's FDA approval, controlled-substance schedule, general dosing framework, and major drug interaction warnings come from the FDA label and are stable regulatory facts. Plausible but not confirmed here: the specific dollar figures for Minnesota cash-pay pricing, Medicaid PA approval rates, and individual insurer tier placements, none of which were verified against a current primary source for this draft. Not established by this article: any claim that a specific savings card amount, compounding price, or Medicaid approval percentage currently applies in Minnesota. A reader who needs an exact, current number for a specific plan or pharmacy should verify it directly rather than rely on any figure that cannot be traced to a dated primary source.